Biotech stock events likely to occur in July or mid-2020 | Biotech Message Board Posts

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  33216 of 33845  at  7/4/2020 11:24:20 AM  by

Cougar3


Biotech stock events likely to occur in July or mid-2020


Drug Stage Catalyst Market Cap

ALBO – Albireo Pharma Inc.

Odevixibat (A4250) - PEDFIC- 1

Progressive familial intrahepatic cholestasis (PFIC)

Phase 3 Phase 3 top-line data due mid-2020.
$388.7 million

ALEC – Alector Inc.

AL001

Frontotemporal Dementia

Phase 2 Phase 2 data likely to be presented at AAIC meeting July 27-31, 2020.
$1.9 billion

AZN – Astrazeneca PLC

AZD1222 (ChAdOx1 nCoV-19)

COVID-19 vaccine

Phase 1 Phase 1 data due July 2020. Phase 3 data due August/September 2020.
$141.2 billion

BLU – BELLUS Health Inc.

BLU-5937

Chronic cough

Phase 2 Phase 2 data due July 2020.
$724.2 million

BTAI – BioXcel Therapeutics Inc.

BXCL501 (SERENITY I)

Schizophrenia - Agitation

Phase 3 Phase 3 data due July 2020.
$1.1 billion

GRTS – Gritstone Oncology Inc.

GRANITE-001 (GO-004)

Solid tumors

Phase 1/2 Phase 1 data due July 13, 2020.
$245.2 million

ITCI – Intra-Cellular Therapies Inc.

Lumateperone ITI-007-402

Bipolar depression

Phase 3 Phase 3 top-line data due mid-2020.
$1.6 billion

JAZZ – Jazz Pharmaceuticals plc

JZP-258

Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

PDUFA priority review PDUFA data under priority review July 21, 2020.
$6.1 billion

LLY – Eli Lilly and Company

LY3127804

COVID-19

Phase 2 Phase 2 data due June 2020. (Entry moved to July 2020 due to missed timeline).
$156.7 billion

MESO – Mesoblast Limited

MPC-06-ID

Chronic low back pain

Phase 3 Phase 3 data mid-2020.
$1.3 billion

MRNA – Moderna Inc.

mRNA-1273

Coronavirus COVID-19 vaccine

Phase 2a Phase 2a dosing has commenced - noted May 29, 2020. Safety data likely due around July 2020. Interim efficacy data due 2H 2020. Further Phase 1 data likely around July. Phase 3 trial to start July 2020.
$21.7 billion

NVAX – Novavax Inc.

NVX-CoV2373

Coronavirus COVID-19 vaccine

Phase 1/2 Phase 1 trial initiation announced May 25, 2020 with preliminary immunogenicity and safety results expected in July 2020.
$4.8 billion

OSMT – Osmotica Pharmaceuticals plc

RVL-1201

Blepharoptosis

PDUFA PDUFA date July 16, 2020.
$381.1 million

PFE – Pfizer Inc., BNTX – BioNTech SE

BNT162

Coronavirus COVID-19

Phase 2Phase 1/2 initial U.S. data released July 1, 2020. SARS-CoV-2 neutralizing antibodies 1.8- and 2.8-times the level of recovered patients exhibited. Further data due mid-July, 2020 from German trial, with data from other three trials due likely in July. Phase 2b/3 trial to be initiated late in July.
$191.7 billion


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 13     Views: 318
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...